Can UCB's Bimekizumab Go From Last To First In Psoriasis?

Skin Clearance Data Tops Rivals

 
• By Kevin Grogan
  
Racing
UCB hopes bimekizumab can overtake Cosentyx for psoriasis • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Immunological

More from Therapeutic Category